Reviews in Medical Virology最新文献_第2页

Crosstalk Between Innate Immunity and Autophagy in Viral Myocarditis Leading to Dilated Cardiomyopathy. 病毒性心肌炎导致扩张型心肌病的先天性免疫与自噬之间的相互关系

IF 9 2区医学

Reviews in Medical Virology Pub Date : 2024-11-01 DOI: 10.1002/rmv.2586

Chen Wang, Honglin Luo

引用次数: 0

Clinical Relevance of Oxidative Stress Biomarkers in Human Flavivirus Infections as Predictors of Disease Progression and Severity. 人类弗拉维夫病毒感染中的氧化应激生物标志物作为疾病进展和严重程度预测因子的临床意义

IF 9 2区医学

Reviews in Medical Virology Pub Date : 2024-11-01 DOI: 10.1002/rmv.70007

Maxim Van Herreweghe, Tess De Bruyne, Nina Hermans, Ralph Huits

{"title":"Clinical Relevance of Oxidative Stress Biomarkers in Human Flavivirus Infections as Predictors of Disease Progression and Severity.","authors":"Maxim Van Herreweghe, Tess De Bruyne, Nina Hermans, Ralph Huits","doi":"10.1002/rmv.70007","DOIUrl":"https://doi.org/10.1002/rmv.70007","url":null,"abstract":"Several Flaviviridae constitute an emerging threat to global health because of their continuing spread and the expansion of vector habitats, largely driven by climate change and intensified global travel. Infections can result in severe neurological or visceral pathologies. The relationship between oxidative stress (OS), an imbalance between generated reactive oxygen species and the antioxidant defences of the host, and flavivirus infection has been repeatedly demonstrated in in vitro and animal studies, but measuring biomarkers of oxidative stress in vivo could prove useful in clinical patient management. We summarise the knowledge and prospects of measuring peripheral OS biomarker levels for clinical case management and correlation with disease severity in six important human flavivirus infections (dengue virus (DENV), Japanese encephalitis virus, West Nile virus (WNV), tick-borne encephalitis virus (TBEV), yellow fever virus and zika virus). We searched the Medline and Web of Science databases for 'Oxidative Stress' AND 'Biomarkers' AND 'Flavivirus', combined with 'clinical', 'in vivo/in vivo', 'patient' and/or 'disease' and included 43 peer-reviewed publications. Correlation between OS and infection has been studied in all six Flaviviridae, but most clinically relevant data are available for DENV, TBEV and WNV. Plasma protein carbonyls, glutathione peroxidase activity and nitrogen monoxide are promising prognostic markers, but their measurement would benefit from methodological harmonisation. Future studies should investigate a broad range of OS biomarkers as predictors of clinically relevant outcomes. We advocate the validation and use of universal or disease-specific oxidative stress indexes that incorporate the most significant outcomes into one, easy-to-use clinical determinant.","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"34 6","pages":"e70007"},"PeriodicalIF":9.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142627170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Underlying Factors Predisposing to Viral-Induced Neurological Diseases. 病毒诱发神经系统疾病的潜在因素。

IF 9 2区医学

Reviews in Medical Virology Pub Date : 2024-11-01 DOI: 10.1002/rmv.2587

Zahra Heydarifard, Paul Shapshak, Milad Zandi

引用次数: 0

Neuroinflammation in Post COVID-19 Sequelae: Neuroinvasion and Neuroimmune Crosstalk. COVID-19 后遗症中的神经炎症：神经入侵和神经免疫串联。

IF 9 2区医学

Reviews in Medical Virology Pub Date : 2024-11-01 DOI: 10.1002/rmv.70009

Roberta S Dos Reis, Sathish Selvam, Velpandi Ayyavoo

{"title":"Neuroinflammation in Post COVID-19 Sequelae: Neuroinvasion and Neuroimmune Crosstalk.","authors":"Roberta S Dos Reis, Sathish Selvam, Velpandi Ayyavoo","doi":"10.1002/rmv.70009","DOIUrl":"10.1002/rmv.70009","url":null,"abstract":"The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 triggered a swift global spread, leading to a devastating pandemic. Alarmingly, approximately one in four individuals diagnosed with coronavirus disease 2019 (COVID-19) experience varying degrees of cognitive impairment, raising concerns about a potential increase in neurological sequelae cases. Neuroinflammation seems to be the key pathophysiological hallmark linking mild respiratory COVID-19 to cognitive impairment, fatigue, and neurological sequelae in COVID-19 patients, highlighting the interaction between the nervous and immune systems following SARS-CoV-2 infection. Several hypotheses have been proposed to explain how the virus disrupts physiological pathways to trigger inflammation within the CNS, potentially leading to neuronal damage. These include neuroinvasion, systemic inflammation, disruption of the lung and gut-brain axes, and reactivation of latent viruses. This review explores the potential origins of neuroinflammation and the underlying neuroimmune cross-talk, highlighting important unanswered questions in the field. Addressing these fundamental issues could enhance our understanding of the virus's impact on the CNS and inform strategies to mitigate its detrimental effects.","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"34 6","pages":"e70009"},"PeriodicalIF":9.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Next Generation RNA/Protein-Carrying Vector With Pleiotropic Activity. 具有多基因活性的下一代 RNA/Protein Carrying Vector。

IF 9 2区医学

Reviews in Medical Virology Pub Date : 2024-11-01 DOI: 10.1002/rmv.70008

Tetsuya Nosaka, Junpei Ohtsuka, Tomomi Ohtsuka, Masayuki Fukumura

{"title":"Next Generation RNA/Protein-Carrying Vector With Pleiotropic Activity.","authors":"Tetsuya Nosaka, Junpei Ohtsuka, Tomomi Ohtsuka, Masayuki Fukumura","doi":"10.1002/rmv.70008","DOIUrl":"10.1002/rmv.70008","url":null,"abstract":"Human parainfluenza virus type 2 (hPIV2), one of the causative agents of infantile common cold, is a non-segmented negative-sense RNA virus with a robust gene expression system. It infects recurrently throughout human life without causing severe disease. Because hPIV2 has a viral envelope that can carry ectopic proteins, we developed a non-propagative RNA/protein-carrying vector BC-PIV by deleting the F gene from hPIV2. BC-PIV can be vigorously proliferated in the stable packaging cell line Vero/BC-F cells expressing the hPIV2 F gene but not in other cells. BC-PIV can deliver exogenous gene(s) on a multigenic RNA genome as an inserted gene fragment(s) and simultaneously deliver exogenous protein(s) on its envelope in a membrane-anchored form. For example, influenza virus M2e protein, Ebola virus GP protein, and severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) spike protein were shown to be highly expressed in packaging cells and incorporated into the virion. The Ebola virus GP protein and SARS-CoV-2 spike protein, each delivered via BC-PIV, efficiently induced neutralising antibodies against each virus, even after prior treatment with recombinant BC-PIV in mice and hamsters, respectively. In this review, we describe the properties of BC-PIV as a promising vaccine vector, and also demonstrate its application as an anti-tumour virus.","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"34 6","pages":"e70008"},"PeriodicalIF":9.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Autoantibodies in COVID‐19 and Other Viral Diseases: Molecular, Cellular, and Clinical Perspectives COVID-19 和其他病毒性疾病中的自身抗体：分子、细胞和临床视角

IF 11.1 2区医学

Reviews in Medical Virology Pub Date : 2024-09-18 DOI: 10.1002/rmv.2583

Srijan Chatterjee, Manojit Bhattacharya, Sanskriti Saxena, Sang‐Soo Lee, Chiranjib Chakraborty

引用次数: 0

Management of Refractory/Resistant Herpes Simplex Virus Infections in Haematopoietic Stem Cell Transplantation Recipients: A Literature Review. 造血干细胞移植受者中难治性/耐药单纯疱疹病毒感染的处理：文献综述。

IF 9 2区医学

Reviews in Medical Virology Pub Date : 2024-09-01 DOI: 10.1002/rmv.2574

Léo Sallée, David Boutolleau

{"title":"Management of Refractory/Resistant Herpes Simplex Virus Infections in Haematopoietic Stem Cell Transplantation Recipients: A Literature Review.","authors":"Léo Sallée, David Boutolleau","doi":"10.1002/rmv.2574","DOIUrl":"10.1002/rmv.2574","url":null,"abstract":"Herpes simplex virus (HSV) infections in allogeneic haematopoietic stem cell transplantation (HSCT) recipients pose significant challenges, with higher incidence, severity, and risk of emergence of resistance to antivirals due to impaired T-cell mediated immunity. This literature review focuses on acyclovir-refractory/resistant HSV infections in HSCT recipients. The review addresses the efficacy of antiviral prophylaxis, the incidence of acyclovir-refractory/resistant HSV infections, and the identification of risk factors and potential prognostic impact associated with those infections. Additionally, alternative therapeutic options are discussed. While acyclovir prophylaxis demonstrates a significant benefit in reducing HSV infections in HSCT recipients and, in some cases, overall mortality, concerns arise about the emergence of drug-resistant HSV strains. Our systematic review reports a median incidence of acyclovir-resistant HSV infections of 16.1%, with an increasing trend in recent years. Despite limitations in available studies, potential risk factors of emergence of HSV resistance to acyclovir include human leucocyte antigen (HLA) mismatches, myeloid neoplasms and acute leukaemias, and graft-versus-host disease (GVHD). Limited evidences suggest a potentially poorer prognosis for allogeneic HSCT recipients with acyclovir-refractory/resistant HSV infection. Alternative therapeutic approaches, such as foscarnet, cidofovir, topical cidofovir, optimised acyclovir dosing, and helicase-primase inhibitors offer promising options but require further investigations. Overall, larger studies are needed to refine preventive and therapeutic strategies for acyclovir-refractory/resistant HSV infections in allogeneic HSCT recipients and to identify those at higher risk.","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"34 5","pages":"e2574"},"PeriodicalIF":9.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141875853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Merkel Cell Polyomavirus-Pathophysiology and Treatment in the Era of Gene-Targeted Therapies. 梅克尔细胞多瘤病毒--基因靶向疗法时代的病理生理学与治疗。

IF 9 2区医学

Reviews in Medical Virology Pub Date : 2024-09-01 DOI: 10.1002/rmv.2580

Trairong Chokwassanasakulkit, Nigel A J McMillan

{"title":"Merkel Cell Polyomavirus-Pathophysiology and Treatment in the Era of Gene-Targeted Therapies.","authors":"Trairong Chokwassanasakulkit, Nigel A J McMillan","doi":"10.1002/rmv.2580","DOIUrl":"10.1002/rmv.2580","url":null,"abstract":"Merkel cell polyomavirus (MCPyV) is a significant contributor to the development of Merkel cell carcinoma (MCC), an aggressive skin cancer with high recurrence and a low survival rate. In fact, it is the deadliest skin cancer. The precise routes of transmission for MCPyV-positive MCC remain unclear, but several factors may trigger its development. Conventional treatments for MCC are not highly effective, especially in patients with metastasis, with a clear need for new treatment options. Gene-targeted therapies hold great promise for the treatment of MCC, including the use of siRNA and CRISPR/Cas (C/Cas) but critically none have yet been translated into clinical trials. Validating this approach is the fact that several siRNA products are already FDA licenced, while C/Cas has entered clinical trial, albeit for conditions other than MCC. There are many challenges that must be overcome to move from preclinical research to the clinic. In this review, we provide a comprehensive summary of the current understanding of MCC, with a particular focus on MCPyV-positive MCC, and the status of gene-targeted therapies. Additionally, we discuss the major obstacles that impede MCC research and explore future prospects.","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"34 5","pages":"e2580"},"PeriodicalIF":9.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development. 关于 RSV 特异性单克隆抗体和抗病毒药物疗效和安全性的系统回顾。

IF 9 2区医学

Reviews in Medical Virology Pub Date : 2024-09-01 DOI: 10.1002/rmv.2576

Andrea T K Sevendal, Siobhan Hurley, Adam W Bartlett, William Rawlinson, Gregory J Walker

{"title":"Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development.","authors":"Andrea T K Sevendal, Siobhan Hurley, Adam W Bartlett, William Rawlinson, Gregory J Walker","doi":"10.1002/rmv.2576","DOIUrl":"10.1002/rmv.2576","url":null,"abstract":"Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infection amongst all ages, causing a significant global health burden. Preventative and therapeutic options for RSV infection have long been under development, and recently, several widely-publicised vaccines targeting older adult and maternal populations have become available. Promising monoclonal antibody (mAb) and antiviral (AV) therapies are also progressing in clinical trials, with the prophylactic mAb nirsevimab recently approved for clinical use in infant populations. A systematic review on current progress in this area is lacking. We performed a systematic literature search (PubMed, Embase, Web of Science, ClinicalTrials.gov, EudraCT, ANZCTR-searched Nov 29th, 2023) to identify studies on all RSV-specific mAbs and AV therapies that has undergone human clinical trials since year 2000. Data extraction focused on outcomes related to the therapeutic efficacy and safety of the intervention on trial, and all studies were graded against the OCEBM Levels of Evidence Table. Results from 59 studies were extracted, covering efficacy and safety data on six mAbs (motavizumab, motavizumab-YTE, nirsevimab, ALX-0171, suptavumab, clesrovimab) and 12 AV therapies (ALN-RSV01, RSV604, presatovir, MDT-637, lumicitabine, IFN-α1b, rilematovir, enzaplatovir, AK0529, sisunatovir, PC786, EDP-938). Of the mAbs reviewed, nirsevimab and clesrovimab hold considerable promise. The timeline for RSV-specific AV availability is less advanced, although EDP-938 and AK0529 have reported promising phase 2 efficacy and safety data. Moving forward, passive immunisation and treatment options for RSV infection will play a significant role in reducing the health burden of RSV, complementing recent advancements in vaccine development. TRIAL REGISTRATION: PROSPERO registration: CRD42022376633.","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"34 5","pages":"e2576"},"PeriodicalIF":9.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142111477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neurological Implications of Poxvirus Infections: Pathogenesis, Neurotropism, and Clinical Manifestations. 痘病毒感染对神经系统的影响：痘病毒感染对神经系统的影响：发病机制、神经侵袭性和临床表现》（Pathogenesis, Neurotropism, and Clinical Manifestations）。

IF 9 2区医学

Reviews in Medical Virology Pub Date : 2024-09-01 DOI: 10.1002/rmv.2581

Mohammed Alissa, Khalid J Alzahrani, Meshari A Alsuwat

引用次数: 0